The invention relates to a dengue virus tetravalent vaccine containing a
common 30 nucleotide deletion (.DELTA.30) in the 3'-untranslated region
of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic
chimeric dengue viruses of serotypes 1, 2, 3, and 4.